Neurological Monitoring in Acute Liver Failure
Alexandra S. Reynolds, Benjamin Brush, Thomas D. Schiano, Kaitlin J. Reilly, Neha S. Dangayach – 11 May 2019
The Gain Is Worth the Pain: Home‐Based Exercise in Liver Transplantation
Michael A. Dunn – 11 May 2019
Fibrosing Cholestatic Hepatitis–Like Syndrome in an Immunocompetent Patient With an Acute Flare of Chronic Hepatitis B
Nigel Sutherland, Christopher Foong Dhin Li Wai Suen, Christopher Mills, Julie Lokan, Marie Sinclair – 11 May 2019
Fibrosing Cholestatic Hepatitis–Like Syndrome in an Immunocompetent Patient With an Acute Flare of Chronic Hepatitis B
Nigel Sutherland, Christopher Foong Dhin Li Wai Suen, Christopher Mills, Julie Lokan, Marie Sinclair – 11 May 2019
Integrated Omics Reveals Tollip as an Regulator and Therapeutic Target for Hepatic Ischemia‐Reperfusion Injury in Mice
Zhen‐Zhen Yan, Yong‐Ping Huang, Xin Wang, Hai‐Ping Wang, Fei Ren, Rui‐Feng Tian, Xu Cheng, Jie Cai, Yan Zhang, Xue‐Yong Zhu, Zhi‐Gang She, Xiao‐Jing Zhang, Zan Huang, Hongliang Li – 11 May 2019 – Hepatic ischemia‐reperfusion (IR) injury is the leading cause of liver dysfunction and failure after liver resection or transplantation and lacks effective therapeutic strategies. Here, we applied a systematic proteomic analysis to identify the prominent contributors to IR‐induced liver damage and promising therapeutic targets for this condition.
Letter to Editor: Prognostic Role of Ammonia in Patients With Cirrhosis
Narendra S. Choudhary, Sanjiv Saigal, Neeraj Saraf, Arvinder S. Soin – 11 May 2019
Deficient IL‐6/Stat3 Signaling, High TLR7, and Type I Interferons in Early Human Alcoholic Liver Disease: A Triad for Liver Damage and Fibrosis
Peter Stärkel, Bernd Schnabl, Sophie Leclercq, Mina Komuta, Ramon Bataller, Josepmaria Argemi, Elena Palma, Shilpa Chokshi, Claus Hellerbrand, Luca Maccioni, Nicolas Lanthier, Isabelle Leclercq – 10 May 2019 – Mechanisms underlying alcohol‐induced liver injury and its progression still remain incompletely understood. Animal models can only address some aspects of the pathophysiology that requires studies directly in humans, which are scarce.
Deficient IL‐6/Stat3 Signaling, High TLR7, and Type I Interferons in Early Human Alcoholic Liver Disease: A Triad for Liver Damage and Fibrosis
Peter Stärkel, Bernd Schnabl, Sophie Leclercq, Mina Komuta, Ramon Bataller, Josepmaria Argemi, Elena Palma, Shilpa Chokshi, Claus Hellerbrand, Luca Maccioni, Nicolas Lanthier, Isabelle Leclercq – 10 May 2019 – Mechanisms underlying alcohol‐induced liver injury and its progression still remain incompletely understood. Animal models can only address some aspects of the pathophysiology that requires studies directly in humans, which are scarce.
LiverLearning®: 2019 Webinar: Management of NAFLD: Integrating Strategies from Obesity Medicine into Clinical Practice
NAFLD is an increasing public health crisis. Although there are no FDA approved medications for the treatment of NAFLD, it is well established that weight loss can improve the metabolic and histologic parameters associated with NAFLD. This webinar will identify key lifestyle changes, pharmacotherapy, and the role of bariatric surgery in obesity management in patients with NAFLD.
Exosomal Transport of Hepatocyte‐Derived Drug‐Modified Proteins to the Immune System
- Read more about Exosomal Transport of Hepatocyte‐Derived Drug‐Modified Proteins to the Immune System
Monday O. Ogese, Rosalind E. Jenkins, Kareena Adair, Arun Tailor, Xiaoli Meng, Lee Faulkner, Bright O. Enyindah, Amy Schofield, Rafael Diaz‐Nieto, Lorenzo Ressel, Gina L. Eagle, Neil R. Kitteringham, Chris E. Goldring, B. Kevin Park, Dean J. Naisbitt, Catherine Betts – 9 May 2019 – Idiosyncratic drug‐induced liver injury (DILI) is a rare, often difficult‐to‐predict adverse reaction with complex pathomechanisms. However, it is now evident that certain forms of DILI are immune‐mediated and may involve the activation of drug‐specific T cells.